Type of Document	Dissertation
Author	Kalgutkar, Amit S.
URN	etd-05222007-091412
Title	Synthesis and biological evaluation of novel MPTP analogs as potential monoamine oxidase B inhibitors
Degree	PhD
Department	Chemistry
Advisory Committee	Advisor Name Title Castagnoli, Neal Jr. Committee Chair Gibson, Harry W. Committee Member Kingston, David G. I. Committee Member Merola, Joseph S. Committee Member Tanko, James M. Committee Member
Keywords	Cyclic teriary amines
Date of Defense	1993-09-01
Availability	restricted
Abstract The Parkinsonian-inducing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and close structural analogs are the only known cyclic tertiary amines with good monoamine oxidase substrate properties. In addition to its substrate properties, MPTP is a weak mechanism-based inactivator of monoamine oxidase-B (MAC)-B). In an attempt to exploit the special interactions between this cyclic tertiary allylamine and MAO-B, studies were initiated to develop novel mechanism-based inactivators of this flavoenzyme. Analogs of MPTP bearing a variety of functional groups at either N or the C(4) position have been synthesized and their interactions with purified MAO-l3 have been characterized. The substituents selected included functionalities which were considered potential sources of enzyme generated electrophilic or radical intermediates that might alkylate and inactivate the enzyme. None of the C(4)-substituted compounds displayed significant enzyme inhibitor properties while the 4-phenyl-I-propargyl analog was a good mechanism-based inactivator of MAO-B but not MAO-A.
Files	Filename       Size       Approximate Download Time (Hours:Minutes:Seconds)     28.8 Modem   56K Modem   ISDN (64 Kb)   ISDN (128 Kb)   Higher-speed Access  LD5655.V856_1993.K354.pdf 10.59 Mb 00:49:02 00:25:13 00:22:04 00:11:02 00:00:56 next to an author's name indicates that all files or directories associated with their ETD are accessible from the Virginia Tech campus network only.

If you have questions or technical problems, please Contact DLA.